Member Info for Kevinl1977

We should be happy at this cheap price. I for one, will be slowly accumulating.

Clinical trials are always going to be at a snails pace. Investors that believe in the product will quietly build their stock until the final chapter. This may be several years later. Patience is the key, data is the key.

Https://www.share-talk.com/top-12-small-cap-stocks-to-watch-in-2025-part-1-avacta/

Loading up, this is all about the data.

The downside is the timeline, but this is the sector we are invested in.

These things take time to prove efficacy and safety.

Trading this may get to a point where it becomes risky?

Exciting times.

Don’t know what the fuss is about on here. Some incredible results, it’s all about the data and proof in P2/3. Buy on the cheap, patience is the key!

Hoping to be rich by 2026.

Many thanks, Timster.

I’m not following at the moment, just look in occasionally.

Anyone got the link, please.

Thanks for sharing, in advance.

It’s pretty easy to read from the RNS:

two prior systemic cancer therapies (range 0-7) with 65% including cytotoxic exposure. Reduction in the sum of longest diameters (SLD) is used to measure response per RECIST 1.1 with partial responses of >30% reduction and minor responses of between >10% and

· Among patients with FAPhigh cancers (n=23), three partial responses and four minor responses were observed, including:

o A durable, confirmed partial response at 12 weeks in a 79-year-old male patient with progressive salivary gland cancer (SGC). After an initial minor response (22% reduction in SLD), the observed durable PR is ongoing despite patient discontinuation due to lifetime maximum dosing (duration of response >18 weeks, with 46.2% reduction in SLD). Tumor histology demonstrates no expression of FAP in tumor cells with only stromal cell expression noted.

o A minor response (14.6% reduction in SLD at first 8-week scan) in a 65-year-old female patient with SGC who remains on the trial. This patient was dosed in the 250 mg/m2 Q2W cohort of the trial and had progression on a prior line of therapy. This patient continues on study. Similarly, the histology shows FAP-negative tumor cells and FAP expression only in the stromal compartment.

o A partial response (40.5% reduction in SLD) in a 55-year-old male patient with dedifferentiated liposarcoma who had progressed on two prior lines of therapy in the metastatic setting. After an initial minor response this patient experienced a partial response with SLD change of -40.6%. The patient experienced new lesions at their latest follow-up scan.

Agreed Hurst.

LTHs don’t need to worry,

I’m building a position, listening to the RNSs.

ATB

Sheppy- guessing that’s where the dog analogy comes from. Are you aware of the sector this share is in and the reasons as to why the SP has dropped? I’ll tell you. It’s due to the very long time scales that it takes to complete the trials to ensure that safety and efficacy is present. It has been known to take 10 years to bring a drug to the market. Obviously this is not a new drug, but a platform, that will take time to prove its worth. Along the way, these trials will be very expensive which means raising money to invest in the processes. This will affect the SP, as with investor sentiment and patience, or lack of it when the data isn’t immediately there. There will be positive news and then news which will affect confidence. Nevertheless, if investors believe in the science they will invest for the LONG TERM. This means another 2-3 years from now! If you don’t have the patience or belief you should sell your shares and move to a company or sector that gives quicker returns or a savings ISA.

The returns here could be huge, IF everything goes to plan. I, for one, will read the RNSs and follow data and qualitative comments in there.

Just saying…

Many thanks for the link, much appreciated.

Unfortunately my close friend has just phoned me tonight to say he has cancer in his throat.

They can’t operate, but have offered radio and chemotherapy for 5 days for 7 weeks.

Is there any point him contacting Avacta to see if he can join a trial to have a larger dosage and hopefully tumour shrinkage or does it have to come through a physician?

Thanks for any sensible advice.

The only offer showing is from 19/10/22 when shares were offered at 0.95p

II

I just saw the email I received at 5pm yesterday, informing me of the company action . I looked this morning in II and it had gone, so missed the moment.

Very naughty and designed to enable cheap shares to be scooped by large investment platforms .

Agreed. Nothing has changed for me. It was guaranteed a raise would come at some point anyway to finance the expensive and extensive trials.

Will have a look in September to see what’s happening with P2.

Nobody wins or loses until you sell.

As WB said, buy low sell high.

Snap the cheap shares up and follow the science.

Good luck LTHs

RNS’s are facts. They don’t lie, otherwise there would be serious repercussions.

So look at the information in the most recent RNS and decide if this is a potential huge opportunity or if you are impatient and are unable to wait until 2026-7 then sell sharpish, imo.

An interesting journey ahead!

You know nothing. This company deals in things way beyond common sense. The only thing people should take notice of are the key dates identified in the RNS.

This was always going to be a rocky road.

Share prices don’t go up in straight lines.

If you believe the science keep buying.

Truant

Are you saying you had insider information?

If so, do you understand the implications that carries :(

This was to be expected, although biggest hit to my trust of AS is the following:

‘anticipate commencing a potential Phase 3 trial in Q1 2026 for AVA6000 (also subject to funding and regulatory approval).’

I think he was quoted as saying we wouldn’t need a P3 trial?